Solvonis Chair to speak at Lucid Capital Markets
Chairman Dennis Purcell to speak at Lucid Capital Markets biotech leadership panel event.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Chair Dennis Purcell to speak at Lucid Capital Markets biotech leadership event.
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders is pleased to announce that its Chairman, Dennis Purcell, will participate in an exclusive investor event hosted by Lucid Capital Markets on Thursday, 17 July 2025 at 2:00pm ET.
The event, moderated by Elemér Piros, PhD, Managing Director and Senior Biotech Analyst at Lucid Capital Markets, features a panel discussion with three of the most influential figures in global biopharma: Dennis Purcell (Chair, Solvonis; Founder, Aisling Capital), Stelios Papadopoulos (Chair, Exelixis), and Jeremy Levin (Chair and CEO, Ovid Therapeutics).
The session will explore leadership, innovation, and strategic capital deployment across the biotechnology sector.
Dennis Purcell brings more than 30 years of experience in life sciences investment, having deployed over $15 billion in more than 200 companies through Aisling Capital. His participation in this panel underscores the strength of strategic leadership at Solvonis as the Company advances its AI-enabled CNS drug discovery platform.
Event details:
Date: Thursday, 17 July 2025
Time: 2:00pm ET / 7:00pm BST
Registration link: https://lnkd.in/eq5pWiFn
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.